Arcturus Therapeutics

Pipeline

Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus’ versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (77 patents and patent applications, issued in the U.S. and other countries). Arcturus’ proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company’s commitment to the development of novel RNA therapeutics has led to collaborations and license agreements with Janssen Pharmaceuticals, Inc. (A Johnson and Johnson Company) and Ultragenyx Pharmaceutical, Inc.

name

LUNAR-CF

indication
Cystic Fibrosis
api
mUNA

INTERNAL mUNA PROGRAMS

RESEARCH

name

LUNAR-OTC

indication
OTC Deficiency
api
mUNA

INTERNAL mUNA PROGRAMS

PRECLINICAL

name

LUNAR-GI

indication
Undisclosed GI Target
api
mUNA

INTERNAL mUNA PROGRAMS

PRECLINICAL

name

LUNAR-HBV

indication
Hepatitis B
api
siUNA

PARTNERED PROGRAMS

PRECLINICAL

name

LUNAR-RARE1

indication
Undisclosed Rare Disease
api
mUNA

PARTNERED PROGRAMS

RESEARCH

name

LUNAR-RARE2

indication
Undisclosed Rare Disease
api
mUNA

PARTNERED PROGRAMS

RESEARCH

name

LUNAR-TTR

indication
TTR Amyloidosis - Partnering Discussions On-going
api
siUNA

INTERNAL PROGRAMS

PRECLINICAL

name

Arbutus, ARB-1467

indication
Hepatitis B
api
siUNA

LICENSED PROGRAMS

CLINICAL

name

Arrowhead, ARC-AAT

indication
Alpha-1-Antitrypsin Deficiency
api
siUNA

LICENSED PROGRAMS

CLINICAL